An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case

Ades, Felipe; Senterre, Christelle; Zardavas, Dimitrios; Azambuja, Evandro de; Popescu, Răzvan; Parent, Florence; Piccart, Martine

doi:10.1016/j.ejca.2014.09.011

Cited by 15 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These countries also share similarities in healthcare decision‐making processes as they face particular challenges in providing highly developed health services compared with more affluent countries: the delays in pricing and reimbursement decisions may be substantial (Ades et al ., ), patient access to high cost technologies in rare diseases is more limited (Iskrov et al ., ), the resources to provide complex biological therapies are fewer (Péntek et al ., ), expensive oncological therapies are rarely affordable (Vladescu et al ., ), and several isolated ethnic groups face access barriers even to basic services (Rechel et al ., ).…”

Section: Introductionmentioning

confidence: 99%

HTA Implementation Roadmap in Central and Eastern European Countries

Kaló

Gheorghe

Huić³

et al. 2016

Health Economics

View full text Add to dashboard Cite

The opportunity cost of inappropriate health policy decisions is greater in Central and Eastern European (CEE) compared with Western European (WE) countries because of poorer population health and more limited healthcare resources. Application of health technology assessment (HTA) prior to healthcare financing decisions can improve the allocative efficiency of scarce resources. However, few CEE countries have a clear roadmap for HTA implementation. Examples from high‐income countries may not be directly relevant, as CEE countries cannot allocate so much financial and human resources for substantiating policy decisions with evidence.Our objective was to describe the main HTA implementation scenarios in CEE countries and summarize the most important questions related to capacity building, financing HTA research, process and organizational structure for HTA, standardization of HTA methodology, use of local data, scope of mandatory HTA, decision criteria, and international collaboration in HTA.Although HTA implementation strategies from the region can be relevant examples for other CEE countries with similar cultural environment and economic status, HTA roadmaps are not still fully transferable without taking into account country‐specific aspects, such as country size, gross domestic product per capita, major social values, public health priorities, and fragmentation of healthcare financing. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

HTA Implementation Roadmap in Central and Eastern European Countries

Kaló

Gheorghe

Huić³

et al. 2016

Health Economics

View full text Add to dashboard Cite

show abstract

“… Delays in time to approval of life‐saving treatment, for example, up to 12 years for trastuzumab approval in some countries (Ades et al ., ) Approximately one‐third of patients with metastatic melanoma do not have access to life‐saving innovative treatment (Kandolf Sekulovic et al ., ) …”

Section: Patients’ Inequalities Priorities and Innovative Solutionsmentioning

confidence: 99%

“…Delays in time to approval of life‐saving treatment, for example, up to 12 years for trastuzumab approval in some countries (Ades et al ., )…”

Section: Patients’ Inequalities Priorities and Innovative Solutionsmentioning

confidence: 99%

The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient‐centric solutions in the mission on cancer

Lorenzo

Apostolidis

2019

Molecular Oncology

View full text Add to dashboard Cite

There is an urgent need for solutions to the economic and social inequalities in cancer care that still exist in many European countries. Patient preferences, ‘big data’, mobile digital technology and molecular and genomic profiling are among the innovative research topics that connect cancer patients to comprehensive cancer centres, and link translational research to cancer diagnosis, treatment and care. The question is whether Europe can deliver the complex infrastructure needed for universal coverage and equitable access to cancer care. The European Cancer Patient Coalition ( ECPC ), the leading ‘umbrella’ cancer patient organisation in Europe, has a central role in bringing the unmet needs of patients with cancer to the forefront of cancer policy, care and research. The ECPC is a respected and reliable partner in the oncology community and has effectively collaborated with institutional stakeholders and organisations, as well as with the European Commission, on cancer research projects and in the development of tools to advance health care and cancer policies at the European and national level. The ECPC believes that innovation cannot emerge and grow without patient involvement and is fully committed to increasing patient education and contribution in cancer research through its active participation in various European cancer research programmes and educational resources. The ECPC is expected to play a major role in the mission on cancer, given its previous achievements in policy and research to help overcome the inequalities in cancer prevention, treatment, rehabilitation and survivorship care. The mission on cancer will be facilitated by active collaboration between patient organisations and scientists, clinicians, politicians and industry, with the aim of identifying important research questions regarding quality of life and social issues for cancer patients of all ages.

show abstract

“…Looking at the cost-effectiveness equation, it is easy to recognize that by increasing the health budget, the weight of "cost" is diminished. It is more likely that countries that spend more on health care adopt new health technologies earlier (35). Also, as a country increases its expenditure in health, it is more likely that drugs are reimbursed earlier and are used in larger quantities.…”

Section: Dealing With the Increasing Costs And The Bureaucracy Barriersmentioning

confidence: 99%

Access to Oncology Drugs in Brazil: Juggling Innovation and Sustainability in Developing Countries

Ades

2017

Medicine Access @ Point of Care

Self Cite

View full text Add to dashboard Cite

Unfortunately, Brazil's inequalities are also seen in the public's access to health care. The Brazilian public health system (SUS-Sistema Único de Saúde) was created with the new Brazilian constitution of 1988 (4), with the purpose to deliver equal, universal, and integral health care to all Brazilian citizens. The public health system is supposed to be organized in a decentralized manner, to locally adapt to the specific health problems of each region from the tropical diseases of the Amazon forest to the pollution-related diseases of its megalopolis. However, it is underfunded, spending around US$150 per patient per year (5, 6). Table I shows the median health expenditure per capita per year in Brazilian metropolitan regions. It is not yet organized or hierarchized to promote its objective and deal with the reallife health problems of its citizens (7). Nontransmissible chronic diseases in Brazil Currently, worldwide, nontransmissible chronic diseases (NTCD) are the major cause of death, accounting for 36 million deaths per year. This group of diseases is composed of cardiovascular diseases, diabetes, lung diseases, and cancer. It has been estimated that 80% of the deaths by NTCD have occurred in middle-and low-income countries. As a convention, deaths caused by these diseases in people under the age of 60 are considered to be premature, as they may reflect the lack of proper health assistance. When comparing NTCD premature deaths, 13% occurred in developed countries, whereas 29% occurred in developing countries.

show abstract

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case

Cited by 15 publications

References 36 publications

HTA Implementation Roadmap in Central and Eastern European Countries

HTA Implementation Roadmap in Central and Eastern European Countries

The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient‐centric solutions in the mission on cancer

Access to Oncology Drugs in Brazil: Juggling Innovation and Sustainability in Developing Countries

Contact Info

Product

Resources

About